CRISPR Therapeutics AG — Director's Dealing 2018

Apr 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-04-16

Reporting Person: Kulkarni Samarth (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-16	Stock Option (Right to Buy)	$19.12	A	75000	Disposed	2027-12-01	Common Shares (75000)	Direct

Footnotes

F1: This performance-based option was granted on December 1, 2017 with respect to 75,000 Common Shares, with 75% of the shares vesting on December 1, 2020 and the remaining 25% of the shares vesting on December 1, 2021.